Jump to content

Cannabinoid Applications In Glaucoma


t-pain
 Share

Recommended Posts

http://www.ncbi.nlm.nih.gov/pubmed/21414525

 

 

CONCLUSIONS:

Some cannabinoid agonists (WIN 55212-2, anandamide) have demonstrated, in experimental studies, to act as ideal drugs in the management of glaucoma, as they have been shown to have good tolerability after topical application, efficiently reduce intraocular pressure, and behave as neuroprotectors on retinal ganglion cells. Further studies as regards the safety and clinical assays must be carried out in order to examine the effectiveness of these drugs for the treatment of glaucoma in our daily clinical practice.

 

 

aha, finally something tells you what they made eye drops from. of course this is a spanish>english machine translated scientific document , so there maybe errors and you should translate the page yourself before putting anything in your eye.

 

Topical application of cannabinoids

Due to the high lipid solubility, and the need to employ lipophilic products for proper dissolution, many vehicles have been tested, such as ethanol, dimethyl sulfoxide, polivinilpyrrolidone, Tween 80, Cremophor, emulphor, bovine serum albumin (BSA), 2-hydroxypropyl -β-ciclodextrino, and currently, it has been popularized Tocrisolve employing TM 67. the TM is a registered Tocrisolve preparation consisting of a vehicle designed for lipophilic compounds, such as cannabinoid and vanilloid agonists. The Tocrisolve TM consists of soybean oil in a ratio of 1:4 with water and is emulsified with the copolymer pluronic F68. Allows dissolve WIN 55212-2 to a concentration of 2%. On the other hand does not require the use of ethanol to promote your solution and has demonstrated a sustained ocular penetration agonist WIN 55212-2 dissolved therein applied topically after 68.

The Δ9-THC, dissolved in mineral oil, was shown to reduce the intraocular pressure equal to or higher than that obtained by pilocarpine (52% reduction), with a more prolonged effect 38,68. This hypotensive effect has been reproduced in other studies with different cannabinoids ( Table 2 ).

 

 

Topical application of Δ9-THC, CBN and CBD has been associated with mydriasis, conjunctival hyperemia, chemosis, severe cases of corneal opacification and neurotoxicity 70. Other ocular side effects associated with systemic administration routes are cannabinoids decrease in tear production, diplopia, accommodation disturbances, photophobia, nystagmus and blepharospasm 7,10,66,70.

 

The use of new solvents such as Tocrisolve TM and the 2-hydroxypropyl-β-ciclodextrino allowed correct cannabinoies dissolving and preparing solutions suitable for ocular application. Although the results to date are promising for application in the field of glaucoma, more safety studies and clinical trials are still necessary to examine the usefulness of these compounds in the treatment of glaucoma in our clinic daily.

Link to comment
Share on other sites

  • 4 years later...

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
 Share



×
×
  • Create New...